(Q36573444)

English

Efficacy of fingolimod is superior to injectable disease modifying therapies in second-line therapy of relapsing remitting multiple sclerosis

scientific article published on 8 December 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

15 August 2017

Efficacy of fingolimod is superior to injectable disease modifying therapies in second-line therapy of relapsing remitting multiple sclerosis (English)

1 reference

Europe PubMed Central

15 August 2017

author name string

Stefan Braune

1

1 reference

Europe PubMed Central

15 August 2017

M Lang

2

1 reference

Europe PubMed Central

15 August 2017

A Bergmann

3

1 reference

Europe PubMed Central

15 August 2017

NeuroTransData Study Group

4

1 reference

Europe PubMed Central

15 August 2017

publication date

8 December 2015

1 reference

Europe PubMed Central

15 August 2017

Journal of Neurology

1 reference

Europe PubMed Central

15 August 2017

263

1 reference

Europe PubMed Central

15 August 2017

2

1 reference

Europe PubMed Central

15 August 2017

327-333

1 reference

Europe PubMed Central

15 August 2017

copyright license

Creative Commons Attribution 4.0 International

8 December 2015

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

https://scigraph.springernature.com/pub.10.1007/s00415-015-7970-6

0 references

Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4751192

30 September 2017

Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4751192

30 September 2017

Implications of real-world adherence on cost-effectiveness analysis in multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4751192

30 September 2017

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4751192

30 September 2017

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4751192

30 September 2017

Treatment patterns in disease-modifying therapy for patients with multiple sclerosis in the United States

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4751192

21 September 2018

Cost-effectiveness of early initiation of fingolimod versus delayed initiation after 1 year of intramuscular interferon beta-1a in patients with multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4751192

21 September 2018

Identifiers

10.1007/S00415-015-7970-6

1 reference

Europe PubMed Central

15 August 2017

1 reference

Europe PubMed Central

15 August 2017

1 reference

Europe PubMed Central

15 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36573444&oldid=1854248282"